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ABSTRACT 
Cefepime monitoring in deproteinized human serum and plasma by micellar electrokinetic 
capillary chromatography and liquid chromatography coupled to mass spectrometry in 
presence of other drugs is reported. For micellar electrokinetic capillary chromatography, 
sample preparation comprised dodecylsulfate protein precipitation at pH 4.5 using an 
increased buffer concentration compared to that of a previous assay and removal of 
hydrophobic compounds with dichloromethane. This provided robust conditions for 
cefepime analysis in the presence of sulfamethoxazole and thus enabled its determination 
in samples of patients that receive co-trimoxazole. The liquid chromatography assay is 
based upon use of a column with a pentafluorophenyl-propyl modified and multi-
endcapped stationary phase and the coupling to electrospray ionization with a single 
quadrupole detector. The performances of both assays with multi-level internal calibration 
were assessed with calibration and control samples and both assays were determined to be 
robust. Cefepime levels monitored by micellar electrokinetic capillary chromatography in 
samples from patients that were treated with cefepime only and with cefepime and co-
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trimoxazole were found to compare well with those obtained by liquid chromatography 
coupled to mass spectrometry. Cefepime drug levels determined by micellar electrokinetic 
capillary chromatography could thereby be validated. 
1 Introduction 
Cefepime (for chemical structure see Fig. 1A) is a parenteral fourth generation 
cephalosporin that has a broad-spectrum in activity against Gram-positive and Gram–
negative bacteria. It is administered for nosocomial infections, infections in 
immunosuppressed or critically ill patients. The dosing schemes range from 1 g every 12 h to 
2 g every 8 h. They also depend on the minimal inhibitory concentration of the causative 
pathogen and the severity of disease. Cefepime penetrates well into the cerebrospinal fluid 
and is eliminated mainly by renal excretion. Almost 90% is excreted unchanged (i.e. as active 
drug) and cefepime clearance correlates well with the creatinine clearance [1]. The half-life 
of cefepime in the serum of patients with normal renal function is 2 h, whereas that in 
patients with end-stage renal disease is 18 h. Cefepime overdose may lead to neurotoxic 
effects, including encephalopathy, neuromuscular excitability, convulsions and coma. To 
ensure therapeutic levels and avoid neurotoxicity, therapeutic drug monitoring (TDM) of 
cefepime should be used. Data gathered thus far suggest that TDM can help to minimize the 
risk of major adverse reactions and to increase drug safety on an individual basis [1–5]. 
Analytical methods for monitoring cefepime in biosamples include bioassays [6], HPLC with 
UV detection [7–10], LC–MS [11,12] and MEKC [5,13–16]. They should be capable of 
accurately monitoring cefepime levels in the range of 1 to 50 µg/mL [5].  
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An MEKC assay based on protein precipitation using SDS at pH 4.5 and hydrodynamic 
injection from the collected supernatant was developed and applied in our laboratory for 
TDM of cefepime [5]. In a 3-year period, TDM with MEKC was applied to more than 1000 
patient samples. The monitored cefepime levels ranged between 1.0 and 131.7 µg/mL (989 
samples). Furthermore, cefepime concentrations were below the LOQ (<1 µg/mL) in 53 
samples and the drug was not detected in 19 samples. Due to an interference with one or 
more compounds, cefepime levels could not be determined in 50 samples. Many of these 
sera contained sulfamethoxazole, which is an active ingredient of co-trimoxazole 
(sulfamethoxazole and trimethoprim). Co-trimoxazole (e.g. Bactrim ®) is an antibiotic 
formulation that is occasionally used together with cefepime in immunosuppressed patients 
(e.g. for Pneumocystis jirovecii prophylaxis and cefepime for treatment of neutropenic 
fever). Sulfamethoxazole could not be separated from cefepime under the used MEKC assay 
conditions. Hence, analyses had to be repeated without co-trimoxazole (i.e. co-trimoxazole 
treatment was stopped about 24 h before blood collection for TDM of cefepime). This 
prompted us to change sample preparation to remove hydrophobic compounds such as 
sulfamethoxazole and to provide conditions that lead to the separation of cefepime and 
residual amounts of sulfamethoxazole. Furthermore, an LC–MS assay for cefepime was 
developed, applied to representative sets of patient samples and used to validate the drug 
levels determined by MEKC. In this paper, modifications of sample preparation for MEKC, 
the performance of the MEKC assay with modified sample preparation, the development 
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and characterization of the LC–MS assay and the comparison of cefepime levels obtained by 
MEKC and LC–MS are presented. 
2 Materials and methods 
2.1 Chemicals, materials and patient samples 
Used reagents were of analytical or research grade. Cefepime dihydrochloride monohydrate 
was obtained from Sandoz Pharmaceuticals (Cham, Switzerland). Ceftazidime pentahydrate, 
obtained from Glaxo (Greenford, Middlesex, UK) or deuterated cefepime-d3 sulfate from 
TRC (Toronto, Canada) were used as internal standards. Sulfamethoxazole was from 
Helvepharm (Schmitten, Switzerland). Sodium acetate, formic acid (98–100%), acetic acid 
(100%) and Na2HPO4  2 H2O were purchased from Merck (Darmstadt, Germany). Na2B4O7  
10 H2O, SDS and ammonium formate were from Fluka (Buchs, Switzerland). 
Dichloromethane was obtained from VWR (Schlieren, Switzerland). Bovine serum (adult) 
was purchased from Sigma (St. Louis, MO, USA) and was used for the preparation of 
calibration and control samples. Patient samples were provided from the University Hospital 
Bern, Switzerland. The analyses were performed within the context of QC. Analysis of 
patient samples was approved by the local ethical committee (KEK-BE 035/2014, SNCTP 
801). 
2.2 MEKC assay with dichloromethane removal of interferences 
2.2.1 Solutions, calibrators and controls 
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The acetate buffer was prepared by dissolving 8.2 g of sodium acetate into 180 mL of water, 
followed by pH adjustment with acetic acid to 4.5 and filling up with water to a final volume 
of 200 mL. Stock solutions of cefepime (100 and 500 µg/mL for preparation of calibrators 
and controls, respectively) and ceftazidime (400 µg/mL, internal standard) were prepared in 
10-fold diluted acetate buffer (pH 4.5) and stored as 0.2 mL aliquots at –70°C. The sample 
preparation reagent was composed of 75 mM SDS in acetate buffer, pH 4.5. For the 
preparation of calibrators, aliquots of 1.0, 5.0, 10.0, 20.0, 40.0, and 60.0 µL of the 100 µg/mL 
cefepime stock solution and aliquots of water (49.0, 45.0, 40.0, 30.0, 10.0, and 0 µL, 
respectively) were added to 100 µL of bovine serum and treated as described in Section 2.2.2. 
Due to internal calibration with a constant amount of the internal standard, this procedure 
provided calibrators with 1.0, 5.0, 10.0, 20.0, 40.0, and 60.0 µg/mL cefepime, respectively. 
Three controls containing 6.0, 25.0, and 45.0 µg/mL cefepime in bovine serum were prepared 
batchwise. Typically, 3.5 mL of a control was produced by combining an appropriate amount 
of the 500 µg/mL cefepime stock solution with bovine serum and aliquots of 100 µL were 
frozen in plastic vials at −70°C. Frozen samples were slowly defrosted and vortex mixed 
before analysis.  
2.2.2 Sample preparation 
Sample preparation is based upon deproteination with SDS at pH 4.5. If not stated 
otherwise, 100 µL of sample (patient sample, control), 20 µL of internal standard solution, 
50 µL of sample preparation reagent and 50 µL of water were combined in a 2.0 mL 
Eppendorf vial. After mixing, 250 µL of dichloromethane was added. The sample was mixed 
again for about 5 s and centrifuged at 13 000 × g for about 10 min at 20°C using a model 
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5415 R Eppendorf centrifuge (Hamburg, Germany). Then, 100 µL of the clear supernatant 
was transferred into a PCR sample vial for analysis. Calibrators were treated the same way 
except that no water was added before centrifugation. 
2.2.3 Instrumentation and running conditions 
MEKC analyses were performed in uncoated fused-silica capillaries of 50 µm id (Polymicro 
Technologies, Phoenix, AZ, USA) and 60 cm (50 cm effective) length using a P/ACE MDQ 
and a PA800plus CE system (Beckman Coulter, Brea, CA, USA). The BGE (separation 
medium) was composed of 6 mM Na2B4O7, 10 mM Na2HPO4, and 75 mM SDS (pH 9.1) and 
is the same as employed previously [5]. Analyses were carried out with an applied voltage of 
15 kV (current: 23.5 µA), analyte detection using the UV detector at 254 nm, and 
hydrodynamic sample injection during 6 s at 1 psi (1 psi = 6894.8 Pa). To increase the 
performance, a short water plug was injected after the sample (3 s at 0.5 psi). The 
temperatures of capillary cartridge and sample holder were maintained at 25 and 25°C, 
respectively. Quantitation was based upon six-point internal calibration in the range of 1.0 to 
60.0 g/mL of cefepime using corrected peak areas (peak areas divided by detection time) for 
data evaluation. Other conditions as reported previously [5]. 
2.3 LC–ESI-MS assay 
2.3.1 Solutions, calibrators and controls 
Stock solutions of cefepime (500, 10 and 1 µg/mL), deuterated cefepime (10 µg/mL) and 
ceftazidime (100 µg/mL) were prepared in 50 mM acetic acid and stored as small aliquots 
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at –70°C. Aliquots of 12.5 and 25.0 µL of the 1 µg/mL cefepime stock standard solution and 
aliquots of 5.0, 15.0, 25.0, 35.0 and 50.0 µL of the 10 µg/ml cefepime stock standard 
solution, together with corresponding amounts of 50 mM acetic acid (37.5, 25.0 µL, 
respectively) and (45.0, 35.0, 25.0, 15.0 and 0 µL, respectively), were added to 50 µL of 
bovine serum thereby producing calibrators with concentration of 0.25, 0.5, 1.0, 3.0, 5.0, 7.0 
and 10.0 µg/mL of cefepime in bovine serum. Three controls containing 0.5, 5.0 and 10.0 
µg/mL of cefepime in bovine serum were prepared. Typically, 2 mL of a control, were 
prepared by combining an appropriate amount of the 500 µg/mL cefepime stock solution 
with bovine serum. Aliqots of 70 µL were stored at –70°C. 
2.3.2 Sample preparation 
Sample preparation was based on deproteination with acetonitrile. Fifty microliters of 
sample (patient sample, control), 10 µL of internal standard solution, 50 µL of 50 mM acetic 
acid and 125 µL of acetonitrile were combined in a 2.0 mL Eppendorf vial, vortexed for 
about 15 s and centrifuged at 13 000 x g for 5 min at 20°C. After centrifugation, 125 µL of 
the clear supernatant was transferred to another Eppendorf vial and combined with 250 µL 
of water. After mixing for 10 s, 125 µL of dichloromethane was added. Sample was mixed 
and centrifuged again. Then, 100 µL of the upper aqueous layer was transferred into the LC–
MS vial and analyzed. Calibrators were treated the same way, except that no acetic acid was 
added before centrifugation.  
2.3.3 Instrumentation and running conditions 
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LC–MS analyses were performed with a PFP Nucleodur HPLC column (i.d. 4.0 mm, length 
125 mm and particle size 5.0 µm, Macherey–Nagel, Oensingen, Switzerland) using a HP 
series 1100 (Hewlett Packard, Waldbronn, Germany) coupled to a Agilent 6120 Single 
Quadrupole LC–MS System with an APCI/ESI interface (Agilent Technologies, Santa Clara, 
California). A gradient elution was applied with solvent A, containing 5 mM ammonium 
formate (pH 3.0), and solvent B comprising 100% acetonitrile. The mobile phase flow rate 
was maintained at 0.5 mL/min. Solvent B was increased from 5 to 20% in the time range 
of 0–10 min (linear gradient). Thereafter, the column was rinsed for 2 min with 50% of 
solvent B at a flow rate of 2 mL/min. Re-equilibration was performed during 3 min at the 
same flow rate with 5% B. The column oven temperature was set to 25°C and the injection 
volume was 10 µL. Nitrogen, provided by a nitrogen generator N2-Mistral-4 (Schmidlin 
Labor, Neuheim, Switzerland), was used as nebulizing and desolvation gas. The flow rate of 
nitrogen was 10 L/min, drying temperature was 300°C and nebulizing pressure was 60 psig. 
The vaporizer temperature was 250°C, the capillary voltage was set to 4000 V and the 
charging voltage was 2000 V. Cefepime, deuterated cefepime-d3 and ceftazidime were 
detected in the positive SIM mode with m/z mass values of 481.1, 484.2 and 547.1, 
respectively. These values correspond to the [M+H]
+
 ions of the three molecules. 
Quantitation was based upon seven-point internal calibration in the range of 0.25 to 10.0 
g/mL of cefepime using peak areas for data evaluation. 
2.4 Determination of recovery 
To determine the recovery of cefepime and the internal standard, spiked samples in water and 
bovine serum were analyzed and the recovery was calculated as the mean ratio between the 
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peak area response of three or four replicates of these samples and the corresponding peak 
area response of equivalent samples in water. 
2.5 Statistical and graphical data analysis 
Data evaluation and presentation was made with SigmaPlot software version 12.5 (Systat 
Software, San Jose, CA, USA). The Mann–Whitney rank sum test was used to compare two 
groups of data. P < 0.05 was considered to be significant. 
3 Results and discussion 
3.1 MEKC analysis of cefepime in presence of sulfamethoxazole 
With our routine MEKC assay, comigration of cefepime with sulfamethoxazole, one of the 
two active compounds present in co-trimoxazole (sulfamethoxazole and trimethoprim), was 
observed [5]. An example of the interference is presented with the electropherogram 
depicted in Fig. 1A. The data represent the analysis of a serum of a patient who received 
both cefepime and co-trimoxazole. Initial efforts to separate cefepime and 
sulfamethoxazole by modification of the BGE composition were not successful. Thus, efforts 
with different sample preparations were investigated to solve this problem. Cefepime and 
ceftazidime are hydrophilic compounds (for chemical structures see inserts in Figs. 1A and 
1C, respectively; logPow values of about –2.7 [17]). Sulfamethoxazole is more hydrophobic 
than cefepime and ceftazidime (for chemical structure see insert in Fig. 1E; logPow value of 
0.89 [18]). Thus, dichloromethane was added to the mixture of serum and sample 
preparation reagent (for composition of sample preparation reagent see Ref. [5]). After 
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mixing and centrifugation, MEKC analysis of the clear aqueous supernatant provided the 
data presented in Fig. 1B. The magnitudes of two peaks (peaks marked with S+CEF and an 
asterisk in Fig. 1A) became much smaller compared to the electropherogram obtained 
without the dichloromethane treatment. Sulfamethoxazole and a second compound which 
could be a metabolite of sulfamethoxazole became extracted and could be analyzed in the 
organic phase (insert of Fig. 1B). Cefepime and ceftazidime were not detected in the organic 
phase. Spiking of the aqueous supernatant with cefepime revealed an electropherogram 
with an enlarged cefepime peak that exhibited a distinct shoulder at its base which is an 
indication of comigration of cefepime with another compound. Finally, the extraction of 
sulfamethoxazole with dichloromethane from the pH 4.5 environment could be confirmed 
using a sulfamethoxazole standard (data not shown). The data revealed that the extraction 
efficiency for sulfamethoxazole was about 85%. Thus, the peak in the electropherogram 
presented in Fig. 1B (marked “CEF?”) does contain a residual amount of sulfamethoxazole 
which falsifies the analytical result. With the calibration for cefepime, a drug level of 17.3 
µg/mL was calculated. This is much less compared to the value obtained when the entire 
peak of Fig. 1A is used for quantification (123.9 µg/mL). These data illustrate that a further 
modification of the sample preparation was required for proper MEKC analysis of cefepime 
in such a sample.  
A change in the preparation of the acetate buffer for the sample preparation reagent 
provided the anticipated breakthrough. For the assay described previously [5], the acetate 
buffer was made from a 0.5 M acetic acid to which 0.5 M sodium acetate solution was 
www.jss-journal.com Page 12 Journal of Separation Science 
 
 
This article is protected by copyright. All rights reserved. 
12 
 
added until pH 4.5 was obtained (estimated buffer composition: 0.500 M acetic acid and 
0.177 M NaOH). In the work described here, the acetate buffer was prepared with a 0.500 
M sodium acetate solution whose pH was adjusted with acetic acid to 4.5 (Section 2.2.1, 
estimated composition of 1.413 M acetic acid and 0.500 M NaOH). Using this buffer with 
about 2.8-fold higher concentration in the sample preparation reagent, resolution between 
cefepime and sulfamethoxazole became possible. This is illustrated with the analysis of the 
same patient sample for which a small cefepime peak of 3.8 µg/mL was now detected 
before a large sulfamethoxazole peak (Fig. 1C). Furthermore, the small peak detected before 
the internal standard (marked with # in panels A and C of Fig. 1) could not be separated 
from the internal standard (Fig. 1C). The small peak is an impurity of ceftazidime used as 
internal standard and was not detected under the conditions of Fig. 1A when the internal 
standard was omitted. Finally, sample preparation with extraction of sulfamethoxazole with 
dichloromethane as described in Section 2.2.2 provided the data of Fig. 1D. Comparison 
with panel C reveals the same amount of cefepime (4.1 µg/mL) and a much reduced peak of 
sulfamethoxazole and the peak marked with an asterisk were monitored in the aqueous 
phase. These data visualize that dichloromethane does not completely remove 
sulfamethoxazole. Analysis of the organic phase provided two peaks (insert in Fig. 1D) which 
is comparable to the analysis with the previous sample matrix (insert in Fig. 1B). 
Furthermore, spiking of the aqueous phase of Fig. 1D with cefepime and reanalysis resulted 
in a much enlarged sharp peak for cefepime (Fig. 1E). Thus, the sample matrix change 
associated with the acetate buffer in the sample preparation reagent led to the separation 
www.jss-journal.com Page 13 Journal of Separation Science 
 
 
This article is protected by copyright. All rights reserved. 
13 
 
of cefepime and sulfamethoxazole and the use of dichloromethane removed a large portion 
of sulfamethoxazole from the sample. Both effects were combined in the modified MEKC 
assay and referred to as MEKC-DCM in the remaining part of this paper. Characterization of 
the modified assay with data comparison to those obtained with the routine MEKC method 
is described below. It is important to note, that BGE composition, sample injection and 
applied voltage were kept the same as in the previous assay [5]. No efforts were undertaken 
to investigate the reasons for the impact of acetate buffer composition on the MEKC 
separation of cefepime and sulfamethoxazole.  
3.2 MEKC assay characterization with dichloromethane removal of interferences 
With the new sample preparation, internal standard and cefepime were detected around 9 
and 11 min, respectively, and the current was about 24 µA, values that are comparable to 
those under the previous assay conditions [5]. Electropherograms obtained with the three 
control samples comprising 6.0 g/mL cefepime (panel A), 25.0 g/mL cefepime (panel B) 
and 45.0 g/mL cefepime (panel C) and a typical patient sample (panel D) are presented in 
Fig. 2. Both, cefepime and ceftazidime are depicted to form sharp peaks. Table 1 
summarizes the analytical characteristics of the six-level internal calibration for 6 
consecutive sets of data. The calibration graphs were found to be linear (r2  0.9991) with F 
values  4360 (P < 0.001). Mean values for the slope and r2 were 0.0110 mL/µg and 0.9995, 
respectively. Furthermore, the mean of the y intercept was –0.0044, a value which is 
significantly smaller than the ratio produced by the smallest calibrator. The recovery 
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assessed for cefepime levels of 5 and 60 g/mL were determined to be 105.7 and 98.4%, 
respectively. Corresponding values for ceftazidime were 108.9 and 98.8%, respectively. The 
limit for quantitation was taken as 1 g/mL (smallest calibrator) and the detection limit was 
determined to be 0.5 g/mL (S/N=3). Typical assay imprecision data for detection times and 
drug levels obtained for the analysis of the three control samples are summarized in Table 2. 
Intraday and interday (n=6) RSD values for the detection times were < 0.7 and < 1.6%, 
respectively. Intraday and interday drug level repeatabilities were found to be  3.1 and  
5.5%, respectively. All these data compare favorably with those obtained previously [5] and 
illustrate that the MEKC-DCM assay is robust and suitable for TDM. Analysis of human 
plasma with EDTA as anticoagulant instead of human serum resulted in indistinguishable 
electropherograms. Thus, plasma patient samples were analyzed with the same assay. 
Comparison of cefepime levels determined with the two MEKC methods for 128 patient 
samples whose electropherograms did not exhibit apparent interferences with cefepime 
shows excellent agreement between the two assays. Evaluation with the Mann–Whitney 
rank sum test revealed no statistically significant difference between the two input groups 
(P = 0.701). Linear regression analysis of the 128 data pairs revealed a linear relationship (r2 
= 0.941) described by the equation MEKC = 0.94 x MEKC-DCM + 0.47 which is very close the 
line of equality (Fig. 3A). Plotting the difference of the two values (MEKC – MEKC-DCM) 
against the mean shows excellent consistency between the two methods (Fig. 3B). The 
mean of the differences and SD were –0.80 and 3.25 g/mL, respectively, indicating that on 
average the MEKC-DCM method gave slightly higher amounts than the assay without the 
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dichloromethane treatment. This difference might be a result of inconsistent calibrations. It 
is, however, insignificant and has no consequences for TDM of cefepime.  
3.3 Characterization of the LC–MS assay and data comparison to MEKC 
LC–MS chromatograms obtained with a blank (panel A), a calibrator comprising 10.0 g/mL 
cefepime (panel B) and a patient sample containing 4.2 g/mL cefepime (panel C) are 
presented in Fig. 4. Both, cefepime and ceftazidime are detected as nicely separated peaks. 
Calibration results of 6 consecutive sets of data are presented in Table 1. The calibration 
graphs were found to be linear (r2  0.9908) with F values  534 (P < 0.001). Comparable 
data were obtained with deuterated cefepime-d3 as internal standard despite that the 
signal at m/z 484.2 contained a small contribution from cefepime (2.4% of cefepime 
abundance according to isotope distribution calculated with Isotope Distribution Calculator 
(www.sisweb.com/mtools/sotope.htm); data not shown). In analogy to the analysis of 
cefepime by MEKC, all data discussed below are for ceftazidime as internal standard. The 
recovery assessed for cefepime levels of 1 and 10 g/mL were determined to be 72.7 and 
74.0%, respectively. Corresponding values for ceftazidime were 71.3 and 73.9%, 
respectively. The matrix effect defined as the ratio of peak area response in presence of 
matrix and absence of matrix components [19] was 1.1 in all cases. The limit for quantitation 
was taken as 0.25 g/mL (smallest calibrator) and the detection limit was determined to be 
0.1 g/mL (S/N=3). Assay imprecision data for detection times and drug levels obtained for 
the analysis of the three control samples are summarized in Table 2. Intraday and interday 
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(n=6) RSD levels for the detection times were < 0.5 and < 1.3%, respectively. Intraday and 
interday drug level repeatabilities were found to be  4.3 and  5.4%, respectively. All these 
data indicate that the LC–MS assay is robust. It is important to note that samples containing 
more than 10 µg/mL cefepime were diluted before analysis.  
The mean ± SD (median, range) of the 128 cefepime levels determined by MEKC-DCM and 
LC–MS were determined to be 21.42 ± 16.10 (16.26, 2.66 – 71.84) g/mL and 22.10 ± 16.37 
(17.35, 2.39 – 77.49) g/mL, respectively. Comparison of the two sets of data with the 
Mann–Whitney rank sum test revealed no statistically significant difference between the 
two input groups (P = 0.682). Comparison of cefepime levels found in patient serum samples 
using the two methods shows excellent agreement between the two methods. Linear 
regression analysis of the 128 data pairs revealed a linear relationship (r2 = 0.977) described 
by the equation LC–MS = 1.01 x MEKC-DCM + 0.58 which is very close the line of equality 
(Figure 5A). Plotting the difference of the two values (LC–MS – MEKC-DCM) against the 
mean, shown in panel B of Figure 5, again shows excellent consistency between the two 
methods. The mean of the differences (SD) was –0.68 (2.47) g/mL, indicating that, on 
average, the MEKC-DCM method resulted in slightly lower amounts compared to the LC–MS 
method. This difference, however, is insignificant and has no consequences for TDM of 
cefepime. In analogy, comparative data analysis of the 128 cefepime levels obtained with 
MEKC (Fig. 3) and LC–MS revealed a linear relationship with a coefficient of determination r2 
of 0.938, a slope of 1.03 and a y intercept of 0.96 µg/mL. The bias, expressed by the mean of 
the differences of the corresponding data pairs, and its SD were 1.48 and 4.07 µg/mL, 
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respectively. Comparison of the two sets of data with the Mann–Whitney rank sum test 
revealed no statistically significant difference between the two input groups (P = 0.451). 
Thus, for the given set of samples, the data obtained with MEKC-DCM and MEKC could be 
validated by LC–MS. 
3.4 Results with samples of patients receiving co-trimoxazole and other potential 
interferences 
With our previous MEKC assay [5], a number of samples could not be analyzed due to 
interferences, including those associated with sulfamethoxazole (Fig. 1). If not carefully 
investigated by peak shape analysis as described previously [5], the use of this assay could 
lead to unrealistic cefepime levels as is shown with the data of samples 1 to 6 presented in 
Fig. 6A. The determined cefepime levels (MEKC data of Fig. 6A) are much higher compared 
to those monitored with the modified sample preparation (MEKC-DCM data). The 
correctness of the latter cefepime levels could be confirmed by LC–MS (Fig. 6A). MEKC-DCM 
and LC–MS analysis of samples from patients that received both cefepime and co-
trimoxazole revealed cefepime levels that compare well (Fig. 6B). For the 38 samples whose 
data are presented in Fig. 6B, linear regression analysis of the data pairs revealed a linear 
relationship with a coefficient of determination r2 of 0.988, a slope of 1.02 and a y intercept 
of 0.42 µg/mL. This is very close to a line of equality. Furthermore, comparison of the two 
sets of data with the Mann–Whitney rank sum test revealed no statistically significant 
difference between the two input groups (P = 0.975). It is interesting to note that the 
second compound extracted with dichloromethane (panels B and D of Fig. 1) was found in 
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all 38 samples. This suggests that it represents a metabolite of sulfamethoxazole. These data 
demonstrate that the MEKC-DCM assay is suitable to properly handle patient samples that 
contain sulfamethoxazole.  
Furthermore, it is important to mention that compounds other than sulfamethoxazole, 
which are not hydrophobic and are thus not removed by dichloromethane but are detected 
in proximity of cefepime or the internal standard, may still produce interferences. Analysis 
of critical samples by MEKC-DCM, including those of Fig. 4 in [5], however, was 
straightforward. Cefepime levels determined by MEKC-DCM were found to compare well 
with those obtained with LC–MS. Drug levels of two examples, whose electropherograms 
are presented in Fig. 6C, are presented as samples 7 and 8 in Fig. 6A. These two samples 
stem from critically ill patients that received multiple drugs. Sample 7 is the patient serum 
whose data are presented in Fig. 4B of the previous paper [5] for which cefepime was 
detected at the front edge of a broad interference of unknown identity (graph a of Fig. 6C). 
With the MEKC-DCM assay cefepime could be detected interference-free whereas 
resolution between the internal standard and a broad peak detected shortly thereafter was 
diminished (Fig. 6C, compare graphs a and b). The cefepime level determined was almost 
identical to that obtained with LC–MS and somewhat higher than that measured by MEKC 
(Fig. 6A). Similar results were obtained with sample 8 (Fig. 6A, upper graphs in Fig. 6C). It is 
important to note that the complexity of these electropherograms is not observed 
frequently. Typically, very few peaks other than those of cefepime and the internal standard 
are monitored (Fig. 2D; examples given in [5]). Thus, to avoid interferences with 
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sulfamethoxazole and other neutral compounds, the previously described MEKC assay 
should be replaced with the MEKC-DCM method described in this paper. With MEKC-DCM, 
analysis of both the sample and the same sample fortified with a small amount of cefepime 
is also recommended to verify peak assignment (for examples see Ref. [5]). 
4 Concluding remarks 
Sample preparation for MEKC analysis of cefepime in serum and plasma was modified to 
provide resolution between cefepime and sulfamethoxazole and to remove a large part of 
sulfamethoxazole from the sample with dichloromethane. With these changes, MEKC can be 
used to analyze cefepime in samples of patients that receive cefepime and co-trimoxazole. 
It provided also good data with other samples of critically ill patients that received multiple 
drugs. The performance of the improved MEKC assay with multi-level internal calibration 
was assessed and determined to be robust. Cefepime levels of representative sets of 
samples stemming from patients that were treated with cefepime only and with cefepime 
and co-trimoxazole were found to compare well with those of a laboratory developed LC–
MS assay. Cefepime drug levels determined by MEKC could thereby be validated. The data 
presented suggest that MEKC can be efficiently used for TDM of cefepime. The MEKC 
method is not better than LC–MS. However, it represents an attractive alternative to LC–MS 
for laboratories that do not have LC–MS instrumentation. The costs of the assay and the 
amounts of chemicals required for analysis are lower compared to those associated with 
LC–MS. 
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Figure 1: MEKC electropherograms obtained for a patient sample comprising 
sulfomethoxazole by analysis (A) with sample matrix of the routine method [5], (B) of the 
aqueous phase after extraction with dichloromethane from the same sample matrix, (C) 
with the new sample matrix, (D) of the aqueous phase after extraction with 
dichloromethane from the new sample matrix, and (E) of sample D spiked with cefepime. 
The inserts in panels B and D depict corresponding electropherograms obtained for the 
analysis of the organic phases. The chemical structures of cefepime, ceftazidime and 
sulfomethoxazole are given as inserts in panels A, C and E, respectively. Key: CEF, cefepime; 
IST, internal standard (ceftazidime); S, sulfamethoxazole; * coextracting compound; # 
impurity of internal standard.  
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Figure 2: Electropherograms obtained with the MEKC-DCM assay for bovine serum controls 
comprising (A) 6.0 g/mL cefepime, (B) 25.0 g/mL cefepime and (C) 45.0 g/mL cefepime 
together with 80.0 g/mL ceftazidime, and (D) a patient sample whose cefepime level was 
determined to be 42.8 g/mL. Key: CEF, cefepime; IST, internal standard (ceftazidime). 
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Figure 3. (A) Comparative cefepime levels and (B) bias analysis data for 128 patient samples 
determined by MEKC and MEKC-DCM. In panel A, the solid line represents a correlation 
graph determined by linear regression analysis, the broken lines describe the 95% prediction 
interval around the regression line and the dotted lines are the 95% confidence interval for 
the regression line. The data of panel B represent difference vs. mean of each data pair. The 
solid lines represent mean and mean  2 SD of the data. The broken line is a graph 
determined by linear regression analysis. 
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Figure 4. LC–MS chromatograms (combined mass traces of 481.1 and 547.1) obtained with 
(A) a blank, (B) a calibrator comprising 10.0 g/mL cefepime and (C) a patient sample whose 
cefepime level was determined to be 4.2 g/mL. Key: CEF, cefepime; IST, internal standard 
(ceftazidime). 
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Figure 5. (A) Comparative cefepime levels and (B) bias analysis data for 128 patient samples 
determined by MEKC-DCM and LC–MS. In panel A, the solid line represents a correlation 
graph determined by linear regression analysis, the broken lines describe the 95% prediction 
interval around the regression line and the dotted lines are the 95% confidence interval for 
the regression line. The data of panel B represent difference vs. mean of each data pair. The 
solid lines represent mean and mean  2 SD of the data. The broken line is a graph 
determined by linear regression analysis. 
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Figure 6. (A) Comparison of cefepime levels of 8 patient samples determined by MEKC, 
MEKC-DCM and LC–MS. (B) Comparative cefepime levels determined by MEKC-DCM and LC–
MS of samples from 38 patients that were under pharmacotherapy with cefepime and co-
trimoxazole (explanations as in Fig. 3). (C) MEKC and MEKC-DCM electropherograms of 
sample 7 of Fig. 6A (graphs a and b, respectively) and sample 8 of Fig. 6A (graphs c and d, 
respectively). 
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Table 1: Statistical evaluation of calibration data a) 
 
Assay Slope y-intercept r2 F value 
mean 
[mL/µg] 
RSD 
[%] 
range mean range mean F P 
MEKC b) 0.0110 2.43 -0.0092‒ -0.0009 -0.0044 0.9991‒1.0000 0.9995  4360.3 < 0.0001 
LC-MS b) 0.1508 8.76 -0.0167‒0.0112 -0.0039 0.9908‒0.9998 0.9963  534.2 < 0.0001 
a) The assigned concentration values and ratios of corrected peak areas (cefepime/IST) were taken 
as x-axis and y-axis values, respectively. 
b) Interday calibration from 6 consecutive sets of data. 
 
a) Table 2: Typical imprecision data for cefepime assessed with control samples 
 
Assay target 
level 
[g/mL] 
Intraday imprecision a) Interday imprecision a) 
IST time 
[min] 
Cefepime 
time 
[min] 
Drug level 
[g/mL] 
IST time 
[min] 
Cefepime 
time 
 [min] 
Drug level 
[g/mL] 
MEKC 6.0 8.96 (0.62) 10.90 (0.55) 5.63 (3.14) 8.92 (1.34) 10.81 (1.48) 5.9 (5.51) 
 25.0 8.96 (0.61) 10.89 (0.47) 24.78 (1.55) 8.93 (1.42) 10.82 (1.51) 23.7 (3.35) 
 45.0 8.96 (0.51) 10.88 (0.41) 47.24 (2.71) 8.94 (1.39) 10.83 (1.48) 43.7 (3.74) 
LC-MS 0.5 9.13 (0.35) 6.08 (0.16) 0.52 (1.90) 9.11 (0.53) 6.09 (0.86) 0.49 (4.48) 
 5.0 9.12 (0.22) 6.07 (0.19) 5.30 (4.29) 9.08 (0.60) 6.07 (1.34) 5.10 (5.42) 
 10.0 9.09 (0.34) 6.09 (0.44) 9.75 (1.68) 9.10 (0.80) 6.09 (1.16) 10.27 (4.43) 
a) mean values (RSD, %) for n=6 (number of repeats)  
 
